EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Sex Differences in the Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta‐Analysis

Yucheng Yang, Liyun He, Shumeng Han, Na Yang, Yiwen Liu, Xuechen Wang, Ziyi Li iD, Fan Ping iD, Lingling Xu, Wei Li, Huabing Zhang iD, Yuxiu Li iD

Journal of Diabetes · 2025-03 · 17 (3)

DOI: 10.1111/1753-0407.70063 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Diabetes, online erschienen am 05.03.2025. Verfasst von Yucheng Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Translation Medicine Center, Peking Union Medical College…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Obesity. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, National High Level Hospital Clinical Research Funding, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To verify sex differences of GLP‐1RAs for weight reduction.

Methods

We searched RCTs reporting weight change by sex from PubMed, Web of Science, Embase, Cochrane Library, and ClinicalTrials registries. Meta‐regression was performed to evaluate the association between weight reduction and sex differences. Subgroup analyses were stratified by individual GLP‐1RA medications, dose, treatment duration, indication, type of control, background treatment, and baseline weight. The study protocol was registered (CRD42023480167).

Results

Fourteen studies covering dulaglutide, exenatide, liraglutide, semaglutide, and retatrutide were included in this study. The meta‐analysis showed that females lost more weight than males (MD 1.04 kg [95% CIs 0.70–1.38]; MD 1.69% [95% CI 0.78–2.61]). The pooled results of GLP‐1RAs indicated similar results (MD 0.88 kg [95% CIs 0.67–1.09]). Meta‐regression illustrated that substantial weight reduction was significantly relevant to greater gender differences ( β = −0.19 [95% CIs −0.29 to −0.09]). Subgroup analysis demonstrated that indications for weight reduction increased the gender difference in weight reduction (MD 4.21 kg [95% CIs 1.75–6.67]). Background treatment, dose, duration of treatment, baseline weight, and type of control had no subgroup differences in the sex difference in weight reduction of GLP‐1RAs. Dulaglutide (MD 0.88 kg [95% CIs 0.63–1.12]) and semaglutide (MD 1.04 kg [95% CIs 0.45–1.63]) showed statistically significant differences in weight reduction between males and females. No gender difference was observed in the exenatide subgroup analysis.

Conclusions

Females lost more weight than males when treated with GLP‐1RAs for weight reduction. The sex difference in weight reduction became more pronounced as the degree of weight reduction increased. Indications for obesity could magnify this sex difference.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsObesityWeight LossFemaleHumansMaleExenatideGlucagon-Like PeptidesImmunoglobulin Fc FragmentsSex CharacteristicsSex FactorsTreatment OutcomeRecombinant Fusion ProteinsGlucagon-Like Peptide 1Semaglutide

Substanzen

ExenatideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsGlucagon-Like Peptide 1Semaglutidedulaglutide

Autor:innen und Institutionen

  • Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Translation Medicine Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical…
  • Diabetes Research Center of Chinese Academy of Medical Sciences, Beijing, China.

ORCID-Profile: Ziyi Li, Fan Ping, Huabing Zhang, Yuxiu Li

Förderung

  • CAMS Innovation Fund for Medical Sciences
  • National High Level Hospital Clinical Research Funding
  • National Natural Science Foundation of China
  • Beijing Municipal Natural Science Foundation
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Yang, Y., He, L., Han, S., Yang, N., Liu, Y., Wang, X., Li, Z., Ping, F., Xu, L., Li, W., Zhang, H., & Li, Y. (2025). Sex Differences in the Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta‐Analysis. Journal of Diabetes, 17(3). https://doi.org/10.1111/1753-0407.70063

Vancouver

Yang Y, He L, Han S, Yang N, Liu Y, Wang X, et al. Sex Differences in the Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta‐Analysis. Journal of Diabetes. 2025;17(3). doi:10.1111/1753-0407.70063

BibTeX
@article{Yang2025,
  author = {Yang, Yucheng and He, Liyun and Han, Shumeng and Yang, Na and Liu, Yiwen and Wang, Xuechen and Li, Ziyi and Ping, Fan and Xu, Lingling and Li, Wei and Zhang, Huabing and Li, Yuxiu},
  title = {Sex Differences in the Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta‐Analysis},
  journal = {Journal of Diabetes},
  year = {2025},
  volume = {17},
  number = {3},
  doi = {10.1111/1753-0407.70063}
}
Kostenlos starten →